AKAN Bio - Regulatory News
Akan Biosciences, Inc receives a MOVE Grant from the Montgomery County Government
Montgomery County, Md. May 19, 2022 -- The Montgomery County Government has approved
a MOVE Grant for the biotech company Akan Biosciences, Inc (Akan) to support their office
space in the County...
AKAN Bio - Regulatory News
FDA Accepted Akan Bio's IND Application for Osteoarthritis
GERMANTOWN, Md., Feb. 16, 2021, Akan Biosciences, LLC (Akan), a Maryland-based, clinical-stage biotech company innovating cellular technology and proprietary manufacturing methods to produce stem cell-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) had accepted the Investigational New Drug Application (IND) for StroMel™, its lead candidate for the treatment of Osteoarthritis of Knee. The active IND enables Akan to start clinical trials.
AKAN Bio - Regulatory News
Akan Biosciences, Inc receives a MOVE Grant from the Montgomery County Government
Montgomery County, Md. May 19, 2022 -- The Montgomery County Government has approved
a MOVE Grant for the biotech company Akan Biosciences, Inc (Akan) to support their office
space in the County...
AKAN Bio - Regulatory News
FDA Accepted Akan Bio's IND Application for Osteoarthritis
GERMANTOWN, Md., Feb. 16, 2021, Akan Biosciences, LLC (Akan), a Maryland-based, clinical-stage biotech company innovating cellular technology and proprietary manufacturing methods to produce stem cell-based therapeutics, today announced that the U.S. Food and Drug Administration (FDA) had accepted the Investigational New Drug Application (IND) for StroMel™, its lead candidate for the treatment of Osteoarthritis of Knee. The active IND enables Akan to start clinical trials.
AKAN Biosciences
Passion. Innovative. Hardworking
Contact us for more information about programs, products and services
AKAN Biosciences
Our Ultimate Goal
The goal is to make stem cell-based anti-inflammatory, regenerative, and reparative products accessible and available to everyone who can benefit from them.